Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1189 results
April 2017
-
Press Release
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
Novartis exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe) Dry eye is an area with high unmet… -
Press Release
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate…
March 2017
-
Press Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the… -
Press Release
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
The unique optical design of the ACTIVEFOCUS(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses… -
Press Release
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to… -
Press Release
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before… -
Press Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced… -
Press Release
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] … -
Press Release
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines. Winning ideas… -
Press Release
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
New analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and… -
Press Release
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…